Cler L., Bu D., Lewis C., Euhus D. (2006). A comparison of five methods for extracting DNA from paucicellular clinical samples. Molecular and Cellular Probes 20, 191-196.
Cordon-Cardo C., O'Brien J.P., Boccia J., Casals D., Bertino J.R., Melamed M.R. (1990). Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. The Journal of Histochemistry and Cytochemistry 38, 1277-1287.
Fromm M.F. (2000). P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. International Journal of Clinical Pharmacology and Therapeutics 38, 69-74.
Geyer J., Döring B., Godoy J.R., Moritz A., Petzinger E. (2005a). Development of a PCR-based diagnostic test detecting a nt230(del4) MDR1 mutation in dogs: verification in a moxidectin-sensitive Australian Shepherd. Journal of Veterinary Pharmacology and Therapeutics 28, 95-99.
Geyer J., Döring B., Godoy J.R., Leidolf R., Moritz A., Petzinger E. (2005b). Frequency of the nt230 (del4) MDR1 mutation in Collies and related dog breeds in Germany. Journal of Veterinary Pharmacology and Therapeutics 25, 545-551.
Geyer J., Klintzsch S., Meerkamp K., Wöhlke A., Distl O., Moritz A., Petzinger E. (2007). Detection of the nt230(del4) MDR1 mutation in White Swiss Shepherd dogs: case reports of doramectin toxicosis, breed predisposition, and microsatellite analysis. Journal of Veterinary Pharmacology and Therapeutics 30, 482-485.
Henik R.A., Kellum H.B., Bentjen S.A., Mealey K.L. (2006). Digoxin and mexiletine sensitivity in a Collie with the MDR1 mutation. Journal of Veterinary Internal Medicine 20, 415-417.
Hugnet C., Bentjen S.A., Mealey K.L. (2004). Frequency of the mutant MDR1 allele associated with multidrug sensitivity in a sample of collies from France. Journal of Veterinary Pharmacology and Therapeutics 27, 227-229.
Jonker J.W., Wagenaar E., van Deemter L., Gottschlich R., Bender H.M., Dasenbrock J., Schinkel A.H. (1999). Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug. British Journal of Pharmacology 127, 43-50.
Kawabata A., Momoi Y., Inoue-Murayama M., Iwasaki T. (2005). Canine mdr1 gene mutation in Japan. The Journal of Veterinary Medical Science 67, 1103-1107.
Martinez M., Modric S., Sharkey M., Troutman L., Walker L., Mealey K. (2008). The pharmacogenomics of P-glycoprotein and its role in veterinary medicine. Journal of Veterinary Pharmacology and Therapeutics 31, 285-300.
Mealey K.L., Bentjen S.A., Gay J.M., Cantor G.H. (2001). Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics 11, 727-733.
Mealey K.L., Northrup N.C., Bentjen S.A. (2003). Increased toxicity of P-glycoprotein-substrate chemotherapeutic agents in a dog with the MDR1 deletion mutation associated with ivermectin sensitivity. Journal of the American Veterinary Medical Association 223, 1453-1455.
Mealey K.L. (2004). Therapeutic implications of the MDR-1 gene. Journal of Veterinary Pharmacology and Therapeutics 27, 257-264.
Mealey K.L., Munyard K.A., Bentjen S.A. (2005). Frequency of the mutant MDR1 allele associated with multidrug sensitivity in a sample of herding breed dogs living in Australia. Veterinary Parasitology 131, 193-196.
Mealey K.L., Gay J.M., Martin L.G., Waiting D.K. (2007). Comparison of the hypothalamic-pituitary-adrenal axis in MDR1-1 Delta and MDR1 wildtype dogs. Journal of Veterinary Emergency and Critical Care 17, 61-66.
Mealey K.L. (2008). Canine ABCB1 and macrocyclic lactones: Heartworm prevention and pharmacogenetics. Veterinary Parasitology 158, 215-222.
Mealey K.L., Fidel J., Gay J.M., Impellizeri J.A., Clifford C.A., Bergman P.J. (2008). ABCB1-1 Delta polymorphism can predict hematologic toxicity in dogs treated with vincristine. Journal of Veterinary Internal Medicine 22, 996-1000.
Mealey K.L., Meurs K.M. (2008). Breed distribution of the ABCB1-1Delta (multidrug sensitivity) polymorphism among dogs undergoing ABCB1 genotyping. Journal of the American Veterinary Medical Association 233, 921-924.
Neff M.W., Robertson K.R., Wong A.K., Safra N., Broman K.W., Slatkin M., Mealey K.L., Pedersen N.C. (2004). Breed distribution and history of canine mdr1-1 Delta, a pharmacogenetic mutation that marks the emergence of breeds from the collie lineage. In: Proceedings of the National Academy of Sciences of the USA 101, 11725-11730.
Nelson O.L., Carsten E., Bentjen S.A., Mealey K.L. (2003). Ivermectin toxicity in an Australian Shepherd dog with the MDR1 mutation associated with ivermectin sensitivity in Collies. Journal of Veterinary Internal Medicine 17, 354-356.
Ose A., Kusuhara H., Yamatsugu K., Kanai M., Shibasaki M., Fujita T., Yamamoto A., Sugiyama Y. (2008). P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier. Drug Metabolism and Disposition 36, 427-434.
Roulet A., Puel O., Gesta S., Lepage J.F., Drag M., Soil M., Alvinerie M., Pineau T. (2003). MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. European Journal of Pharmacology 450, 85-91.
Sartor L.L., Bentjen S.A., Trepanier L., Mealey K.L. (2004). Loperamide toxicity in a collie with the MDR1 mutation associated with ivermectin sensitivity. Journal of Veterinary Internal Medicine 18, 117-118.
Zhou S.F. (2008). Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 38, 802-832.
